Dublin, April 21, 2023 (GLOBE NEWSWIRE) -- The "The U.S. Medical Weight Loss Market" report from Marketdata LLC has been added to ResearchAndMarkets.com's offering.
The $8.8 billion U.S. medical weight loss market grew nearly 17% last year, recovering from the depressed levels of 2020-2021 during the pandemic. The tide has turned toward a greater focus on medical weight loss programs using the new obesity drugs.
The big story of 2022 has been the soaring demand for new obesity drugs such as Wegovy, Ozempic and Saxenda, with more new drugs coming soon. The market may be entering a new era of medical approaches. Even Weight Watchers now provides a medical plan.
Like commercial weight loss centers, medical programs have pivoted to a mix of virtual client meetings and in-person care.
This is the most comprehensive investigation of the medical weight loss market published by anyone worldwide. There are no medical associations or private sector research firms that cover the small and privately-owned medical weight loss chains, franchises, hospitals and clinics.
Covered: dollar value & growth rates of all major medical weight loss market segments (1997 to 2022, 2023 & 2027 forecasts), latest market trends and developments, in-depth analyses of these markets: weight loss surgery, programs by bariatricians, programs by hospitals, clinics, and independent MDs, programs by VLCD (very low calorie diets) vendors, and the prescription obesity drugs market.
Includes:
- Effects of the Pandemic on operations & revenues for all market segments, analysis of the recovery
- How dieter behavior changed with the pandemic
- Findings of interviews with top managements of medical chains
- The skyrocketing market for Rx obesity drugs and MD programs
- Franchising as a growth strategy
- Profit & Loss Statement for a typical medical weight loss center
- Competitive position of medical programs vs. commercial diet centers, DIY plans, retail
- Insurance coverage, the ACA and Medicare, avg. program costs
- Rankings of the leading competitors by revenues, no. of sites.
Key Topics Covered:
Introduction, Scope, Methodology
Executive Overview
- Summary: discussion of medical weight loss mkt. characteristics, limitations, cyclical nature
- Market definition and segments
- Market structure: discussion of various types of programs & providers
- Discussion of total diet market and medical market's major developments since 2021
- How the pandemic changed dieter behaviors
Hospital & Clinic Chains Weight Loss Programs
- Structure of the medical weight loss market, mix and $ value by: hospitals ^ private MD programs, clinic chains & franchises, Rx diet drugs, bariatric surgery, VLCDs
- Status Report: Effects of the pandemic on medical program operations and revenues: The pivot to digital delivery, current hot Rx obesity drugs market and MDs adding Wegovy, Saxenda, Ozempic to their plans, recovery of medical programs since 2020
- Types of plans offered (low-cost, moderate-cost plans, estd. no. of hospitals providing each, typical cost), Medicare coverage
- Interviews with management at HMR, Medi-Weightloss, Weight Loss MD, Karol Clark
- Physician-based diet programs: diet drugs/other methods used, consumer attitudes, limitations, estd. no. MDs with a weight loss program - independents vs. affiliated with chains, meds used, typical cost of MD programs
- Profiles of a hospital-based weight loss program: Johns Hopkins
Major Medical Chains: Company Profiles:
- Lindora Clinics,
- Centers for Medical Weight Loss,
- Smart for Life, Medi-Weightloss Clinics,
- Medical Weight Loss of Michigan,
- Nuviva,
- Dr. G's,
- Let's Lose,
- JumpstartMD,
- Ideal Protein.
Bariatrician (Obesity Medicine Specialists) Programs
- Status report of profession, OMA survey results (MDs by: age, income, size practice), how they're trained, number practicing, certification by OMA, use of diet drugs, treatment methods used, plan effectiveness/cost, business is up due to more surgeries, less surgeries - opinions of industry consultant.
- Estimated $ value of the market for their programs: 2012-2027 F
The Weight Loss (bariatric) Surgery Market
- Status Report: Effects of the pandemic on volume of procedures performed, revenues, 2021-2022 recovery
- Discussion of sleeve, gastric bypass, lap band procedures, outcomes data status report & interviews with ASMBS President, a bariatric practice consultant
- Costs per surgery by type payor, pros/cons, who qualifies, effect of Obamacare on coverage by 25 state exchanges
- Surgery utilization and outcomes, mean cost per surgery, patient demographics
- Major insurers' coverage today, status report, Medicare coverage, role of liaison firms (Obesity Help, Barix Clinics, Journey Lite - addresses), avg. cost of surgery.
- Types of surgery: Roux-en-Y, lap banding, mini-gastric bypass, sleeve, consumer pros/cons
- Associations: ASBS, Obesity Action Coalition, increased lobbying efforts.
VLCD/LCD Fasting Supplement Programs
- Status report of low-calorie modified fasting programs in 2022, effects of the pandemic, outlook by mgmt. at HMR, demand from hospitals for turnkey programs characterizing the mkt. (price, programs, no. of sites, increased direct-to-customer sales)
- Historical nature of market - development from 1970s-1990s, enrollments, drop-out/completion rates, problem on insurance coverage, market indicators, positive/negative trends/factors
- fasting vs. maintenance), $ value of mkt. for 1984-2027 F.
- Company Profiles: Detailed descriptions of companies/plans, program revenues: Health Management Resources, Optifast (Nestle), Robard
The Prescription Diet Drugs Market
- Discussion: Strong recent growth of new Rx drugs (semaglutide) by Novo Nordisk fuels major boost in value of U.S. obesity meds market, MDs adding to their practices, viewing obesity as a disease, major obesity medications used today, role of MDs, commercial chains' involvement with diet drugs, why it has been tougher than thought to develop anti-obesity drugs that are effective and with minimal side effects.
- Status Report: strong sales of Wegovy, Ozempic, Saxenda (Novo Nordisk annual report, $ sales) taken off the mkt., FDA rejections of: Acomplia, Taranabant, other Rx diet drugs
- New obesity drugs in development to 2026: semaglutide, Mounjaro (Lilly)
- Existing drugs used (Xenical, Phentermine) - descriptions
- Marketdata's 2023 and 2027 outlooks for prescription diet drugs, effect of new drugs on mkt. size, discussion of this market's potential vs. drawbacks, overcoming MD and consumer attitudes, side effects, effectiveness. Moderate weight loss not enough for most dieters.
Reference Directory of Weight Loss Information Sources
- Industry & government trade associations, journals, newsletters, magazines, consultants
Companies Mentioned
- Centers for Medical Weight Loss
- Dr. G's
- HMR
- Ideal Protein
- JumptStart MD
- Lindora Clinics
- Medi-Weightloss
- Medical Weight Loss of Michigan
- Nuviva
- Optifast
- Robard
- Smart For Life
For more information about this report visit https://www.researchandmarkets.com/r/pt5auj
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
